Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06350097
Registration number
NCT06350097
Ethics application status
Date submitted
2/04/2024
Date registered
5/04/2024
Date last updated
19/07/2024
Titles & IDs
Public title
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Query!
Scientific title
A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Query!
Secondary ID [1]
0
0
D516NC00001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
TROPION-Lung14
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Osimertinib
Treatment: Drugs - Datopotamab Deruxtecan
Experimental: Arm 1: Osimertinib in combination with Datopotamab Deruxtecan - Participants in this group will receive osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion q3w of Day 1 of every 21-day cycle.
Active comparator: Arm 2: Osimertinib monotherapy - Participants in this group will receive osimertinib 80 mg QD as oral tablet.
Treatment: Drugs: Osimertinib
Arm 1: Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.
Arm 2: Osimertinib 80 mg QD as oral tablet .
Treatment: Drugs: Datopotamab Deruxtecan
Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
To demonstrate the superiority of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of PFS by BICR in all randomised participants.
Query!
Assessment method [1]
0
0
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause (in the absence of progression).
Query!
Timepoint [1]
0
0
It is anticipated that it will be performed approximately 3 years after the first participant is randomised.
Query!
Secondary outcome [1]
0
0
To demonstrate the superiority of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of OS in all randomised participants.
Query!
Assessment method [1]
0
0
OS defined as the time from randomisation until the date of death due to any cause.
Query!
Timepoint [1]
0
0
It is anticipated that it will be performed approximately 7 years after the first participant has been randomised.
Query!
Secondary outcome [2]
0
0
To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of PFS on CNS metastases in participants with CNS metastases at baseline
Query!
Assessment method [2]
0
0
Central nervous system progression-free survival (CNS PFS) is defined as the time from randomisation until the date of objective CNS progression assessed by CNS BICR or death (by any cause in absence of CNS progression).
Query!
Timepoint [2]
0
0
It is anticipated that it will be performed approximately 3 years after the first participant is randomised.
Query!
Secondary outcome [3]
0
0
To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of PFS by investigator in all randomised participants.
Query!
Assessment method [3]
0
0
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by investigator, or death due to any cause (in the absence of progression).
Query!
Timepoint [3]
0
0
It is anticipated that it will be performed approximately 3 years after the first participant is randomised.
Query!
Secondary outcome [4]
0
0
To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of ORR in all randomised participants with measurable disease at baseline.
Query!
Assessment method [4]
0
0
ORR is defined as the proportion of participants who have a confirmed CR or confirmed PR, as determined by BICR (and investigator) per RECIST 1.1.
Query!
Timepoint [4]
0
0
It is anticipated that it will be performed approximately 3 years after the first participant is randomised.
Query!
Secondary outcome [5]
0
0
To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of DoR in all randomised participants with measurable disease at baseline.
Query!
Assessment method [5]
0
0
DoR is defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1, as assessed by BICR (and investigator) assessment or death due to any cause.
The measure of interest is the median of DoR.
Query!
Timepoint [5]
0
0
It is anticipated that it will be performed approximately 3 years after the first participant is randomised.
Query!
Secondary outcome [6]
0
0
To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib on the prevention of CNS metastases
Query!
Assessment method [6]
0
0
Neuro-radiologist assessments according to CNS RECIST 1.1 to determine the presence/absence of CNS lesions at progression in participants without CNS metastases at baseline.
Query!
Timepoint [6]
0
0
It is anticipated that it will be performed approximately 3 years after the first participant is randomised.
Query!
Secondary outcome [7]
0
0
To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of PFS2 in all randomised participants
Query!
Assessment method [7]
0
0
PFS2 will be defined as the time from randomisation to the earliest of the progression event (following the initial progression) subsequent to first subsequent anti-cancer therapy, or death.
Query!
Timepoint [7]
0
0
It is anticipated that it will be performed approximately 7 years after the first participant has been randomised.
Query!
Secondary outcome [8]
0
0
To assess the PK of osimertinib and Datopotamab Deruxtecan
Query!
Assessment method [8]
0
0
Concentration of osimertinib and its metabolite AZ5104, Datopotamab Deruxtecan, total anti-TROP2 antibody and DXd in plasma.
Query!
Timepoint [8]
0
0
It is anticipated that it will be performed approximately 7 years after the first participant has been randomised.
Query!
Secondary outcome [9]
0
0
To investigate the immunogenicity of Datopotamab Deruxtecan
Query!
Assessment method [9]
0
0
Presence of ADAs for Datopotamab Deruxtecan (confirmatory results: positive or negative, titres, and neutralizing antibodies).
Query!
Timepoint [9]
0
0
It is anticipated that it will be performed approximately 7 years after the first participant has been randomised.
Query!
Secondary outcome [10]
0
0
To compare the local EGFR mutation test result used for patient selection with the retrospective central cobas® EGFR Mutation Test v2 results from baseline tumour samples
Query!
Assessment method [10]
0
0
Concordance of EGFR mutation status between the local EGFR mutation test and the central cobas® EGFR Mutation Test v2 results from tumour samples with evaluable results.
Query!
Timepoint [10]
0
0
It is anticipated that it will be performed approximately 3 years after the first participant is randomised.
Query!
Secondary outcome [11]
0
0
To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan vs. osimertinib monotherapy based on the cobas® EGFR Mutation Test v2 plasma screening test result for Ex19del or L858R EGFR mutations
Query!
Assessment method [11]
0
0
PFS by Investigator by plasma EGFR mutation status PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by investigator, or death due to any cause (in the absence of progression).
Query!
Timepoint [11]
0
0
It is anticipated that it will be performed approximately 7 years after the first participant has been randomised.
Query!
Eligibility
Key inclusion criteria
Age
1. Participant must be = 18 years; Participant from Japan must be = 20 years, at the time of signing the ICF.
Type of Participant and Disease Characteristics
2. Histologically or cytologically documented nonsquamous NSCLC.
3. Stage IIIB or IIIC or Stage IV metastatic NSCLC or recurrent NSCLC (based on the American Joint Committee on Cancer Edition 8) not amenable to curative surgery or definitive chemoradiation at the time of randomisation.
4. Participants must not have received prior EGFR TKIs or other systemic therapy for Stage IIIB, IIIC or IV NSCLC.
5. The tumour harbors 1 of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del or L858R), either alone or in combination with other EGFR mutations.
6. For participants enrolled in randomisation period, mandatory provision of an unstained, archival tumour tissue sample in a quantity sufficient to allow for central confirmation of the EGFR mutation status.
7. WHO performance status of 0 or 1.
8. At least one lesion not previously irradiated that qualifies as a RECIST 1.1 TL at baseline and can be accurately measured at baseline as =10 mm in the longest diameter (except lymph nodes, which must have short axis =15 mm) with CT or MRI and is suitable for accurate repeated measurements.
9. Adequate bone marrow reserve and organ function within 7 days before the first dose of study intervention .
Sex and Contraceptive/Barrier Requirements
10. Male and female Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Other Inclusion Criteria
11. All races, gender and ethnic groups are eligible for this study.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Medical Conditions
1. As judged by the investigator, any evidence of diseases (such as severe or uncontrolled systemic diseases, including active bleeding diseases, psychiatric illness/social situations), history of allogenic organ transplant, and/or substance abuse which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardise compliance with the protocol.
2. Refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of osimertinib.
3. History of another primary malignancy.
4. Spinal cord compression and unstable brain metastases.
5. Clinically significant corneal disease.
6. Has active or uncontrolled hepatitis B or C virus infection.
7. Known HIV infection that is not well controlled.
8. Uncontrolled infection requiring i.v. antibiotics, antivirals or antifungals; suspected infections (eg, prodromal symptoms); or inability to rule out infections (participants with localised fungal infections of skin or nails are eligible).
9. Resting ECG with clinically abnormal findings.
10. Uncontrolled or significant cardiac disease.
11. Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.
12. Has severe pulmonary function compromise.
Prior/Concomitant Therapy
13. Prior exposure to any agent including an ADC containing a chemotherapeutic agent targeting topoisomerase I, TROP2-targeted therapy.
Prior/Concurrent Clinical Study Experience
14. Participants with a known history of severe hypersensitivity reactions to either Dato-DXd and osimertinib or any excipients of Dato DXd and osimertinib or drugs with a similar chemical structure or class to DXd and osimertinib.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
29/04/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
25/05/2032
Query!
Actual
Query!
Sample size
Target
582
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Site - Clayton
Query!
Recruitment hospital [2]
0
0
Research Site - Kogarah
Query!
Recruitment hospital [3]
0
0
Research Site - Westmead
Query!
Recruitment postcode(s) [1]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [2]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [3]
0
0
2145 - Westmead
Query!
Recruitment outside Australia
Country [1]
0
0
Canada
Query!
State/province [1]
0
0
Quebec
Query!
Country [2]
0
0
China
Query!
State/province [2]
0
0
Changchun
Query!
Country [3]
0
0
China
Query!
State/province [3]
0
0
Chongqing
Query!
Country [4]
0
0
China
Query!
State/province [4]
0
0
Hankou,Wuhan
Query!
Country [5]
0
0
China
Query!
State/province [5]
0
0
Jinan
Query!
Country [6]
0
0
China
Query!
State/province [6]
0
0
Kunming
Query!
Country [7]
0
0
China
Query!
State/province [7]
0
0
Linhai
Query!
Country [8]
0
0
China
Query!
State/province [8]
0
0
Shanghai
Query!
Country [9]
0
0
China
Query!
State/province [9]
0
0
Wuhan
Query!
Country [10]
0
0
Germany
Query!
State/province [10]
0
0
Berlin
Query!
Country [11]
0
0
Germany
Query!
State/province [11]
0
0
Erfurt
Query!
Country [12]
0
0
Germany
Query!
State/province [12]
0
0
Frankfurt
Query!
Country [13]
0
0
Germany
Query!
State/province [13]
0
0
Immenhausen
Query!
Country [14]
0
0
Germany
Query!
State/province [14]
0
0
Kiel
Query!
Country [15]
0
0
Germany
Query!
State/province [15]
0
0
Köln
Query!
Country [16]
0
0
Germany
Query!
State/province [16]
0
0
München
Query!
Country [17]
0
0
Italy
Query!
State/province [17]
0
0
Monza
Query!
Country [18]
0
0
Italy
Query!
State/province [18]
0
0
Parma
Query!
Country [19]
0
0
Korea, Republic of
Query!
State/province [19]
0
0
Seoul
Query!
Country [20]
0
0
Spain
Query!
State/province [20]
0
0
Barcelona
Query!
Country [21]
0
0
Spain
Query!
State/province [21]
0
0
Granada
Query!
Country [22]
0
0
Spain
Query!
State/province [22]
0
0
La Coruña
Query!
Country [23]
0
0
Spain
Query!
State/province [23]
0
0
Majadahonda
Query!
Country [24]
0
0
Spain
Query!
State/province [24]
0
0
Valencia
Query!
Country [25]
0
0
Taiwan
Query!
State/province [25]
0
0
Tainan
Query!
Country [26]
0
0
Taiwan
Query!
State/province [26]
0
0
Taipei City
Query!
Country [27]
0
0
Taiwan
Query!
State/province [27]
0
0
Taipei
Query!
Country [28]
0
0
Taiwan
Query!
State/province [28]
0
0
Taoyuan
Query!
Country [29]
0
0
Thailand
Query!
State/province [29]
0
0
Bangkok
Query!
Country [30]
0
0
Thailand
Query!
State/province [30]
0
0
Dusit
Query!
Country [31]
0
0
Thailand
Query!
State/province [31]
0
0
Hat Yai
Query!
Country [32]
0
0
Thailand
Query!
State/province [32]
0
0
Mueang Udon Thani
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
AstraZeneca
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Datopotamab Deruxtecan (i.v. infusion) compared with osimertinib (tablet) monotherapy as a first-line therapy in participants with locally advanced or metastatic EGFRm (Ex19del and/or L858R) NSCLC. Study details include: 1. The study duration will be event-driven, with an estimated duration of approximately 9 years. 2. Participants may receive study treatment until disease progression, unacceptable toxicity, or other specific discontinuation criteria are met. 3. The visit frequency will be every 3 weeks during the treatment period. Note: Participants on osimertinib treatment (osimertinib only arm or who have discontinued Datopotamab Deruxtecan while are still receiving osimertinib) are required to attend visits to perform assessments every 6 weeks from Cycle 7 until Cycle 17 and then visits every 12 weeks until disease progression, IP discontinuation or primary PFS DCO. Participants who are receiving osimertinib + Datopotamab Deruxtecan are still required to attend visit to perform assessment every 3 weeks (q3w) per SoA.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06350097
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
AstraZeneca Clinical Study Information Center
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-877-240-9479
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06350097
Download to PDF